Bicara Therapeutics Inc. BCAX
Set alert
9.13 USD -0.60 -6.17%
At close · Oct 30
8.98 -0.15 -1.65%
After hours · Oct 30, 7:42 PM ET
8.36 Day range 9.38
9.13 52-week range 30.40
- YTD
- -45.75%
- 1 year
- -44.53%
- Open
- 9.38
- Prev close
- 9.73
- Mkt cap
- 604.16M
- Vol
- 4.20M
- Avg vol
- 973.12K
- EPS
- -3.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.36
- High
- 9.38
- Forward P/E
- -4.96
- Beta
- -0.69
- Short ratio
- 16.85
- Inst. own
- 102.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 20.82
- 200-d avg
- 21.33
- 1y target
- 35.67
6M chart
Events in this range
- May 11, 2026Earnings: -0.93; estimate -0.64; surprise -45.31%
- Aug 11, 2026Earnings: -0.82; estimate -0.81978; surprise -0.03%
- Aug 12, 2026Rating: Mizuho · Neutral → Neutral
- Aug 12, 2026Rating: Morgan Stanley · Overweight → Overweight
- Aug 12, 2026Rating: Wedbush · Outperform → Outperform
- Aug 12, 2026Rating: Goldman Sachs · Neutral → Neutral
- Aug 19, 2026Rating: BMO Capital · — → Outperform
- Oct 19, 2026Rating: BTIG · Buy → Buy
Signals (27)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 28, 2026 | 4 days ago |
| RSI: Oversold | Oct 28, 2026 | 4 days ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Sep 25, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 23, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 15, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 21, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jul 9, 2026 | 3 months ago |
| RSI: Overbought | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 16, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| SMA: Bearish | May 13, 2026 | 5 months ago |
Key statistics
- Market cap
- 1.16B
- Enterprise value
- 621.56M
- Trailing P/E
- 0.00
- Forward P/E
- -4.96
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.46
- EPS (TTM)
- -3.08
- Beta
- -0.69
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -76.95M
- Total cash
- 497.26M
- Total debt
- 1.16M
- Return on equity
- -41.01%
- Shares outstanding
- 66.17M
- Short % of float
- 22.51%
- 50-day average
- 20.82
- 200-day average
- 21.33
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.67 +290.7% upside
Now 9.13
- Target (low)
- 20.00
- Target (mean)
- 35.67
- Target (high)
- 45.00
Ratings (0m) 14 13 buy · 1 hold · 0 sell
- Strong buy3
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.82167.
Financials — quick view
BCAX Revenue — quarterly 0
BCAX Net income — quarterly -55.44M
BCAX EPS — quarterly -0.82
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.84 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.81978 | -0.82 | 0.00 | -0.03% |
| May 11, 2026 | Mar 31, 2026 | -0.64 | -0.93 | -0.29 | -45.31% |
| Mar 26, 2026 | Dec 31, 2025 | -0.72 | -0.68 | +0.04 | +5.56% |
| Nov 10, 2025 | Sep 30, 2025 | -0.55 | -0.67 | -0.12 | -21.82% |
| Aug 12, 2025 | Jun 30, 2025 | -0.54 | -0.50 | +0.04 | +7.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | BTIG | reit | Buy | Buy |
| Aug 19, 2026 | BMO Capital | init | — | Outperform |
| Aug 12, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Aug 12, 2026 | Wedbush | main | Outperform | Outperform |
| Aug 12, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Aug 12, 2026 | Mizuho | main | Neutral | Neutral |
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bicara.com
News
- Goldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8
- Wedbush Maintains Outperform on Bicara Therapeutics, Lowers Price Target to $24
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Bicara Therapeutics (NASDAQ:BCAX) Given Buy Rating at BTIG Research
- BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target
- Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX
Your note
Sign in to keep a note on BCAX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COHLHEPP RYAN | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 7, 2026 | 181,641 |
| HYEP IVAN | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 9, 2026 | 129,855 |
| MAZUMDAR CLAIRE | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 9, 2026 | 362,152 |
| MEISNER LARA S. | Officer | Conversion of Exercise of derivative security | Sep 28, 2025 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 25, 2026 | 0 |
| RABEN DAVID M.D. | Officer | Conversion of Exercise of derivative security | Apr 26, 2026 | 55,286 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 10.97% | 7,255,993 | 126.83M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 9.58% | 6,338,487 | 110.80M | Jun 29, 2026 |
| Siren, L.L.C. | 8.47% | 5,602,970 | 97.94M | Jun 29, 2026 |
| Vestal Point Capital, LP | 7.93% | 5,250,000 | 91.77M | Jun 29, 2026 |
| Deep Track Capital, Lp | 6.20% | 4,100,000 | 71.67M | Jun 29, 2026 |
| Blackrock Inc. | 5.82% | 3,848,090 | 67.26M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 3.29% | 2,179,330 | 38.09M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.53% | 1,676,653 | 29.31M | Jun 29, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 1.77% | 1,170,492 | 20.46M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.73% | 1,144,022 | 20.00M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.65% | 1,092,258 | 19.09M | Sep 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 1.52% | 1,004,231 | 17.55M | Jun 29, 2026 |